Erectile Dysfunction – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Erectile Dysfunction – Pipeline Review, H1 2017’, provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction

The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects

The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Apricus Biosciences Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Biopharm GmbH

Can-Fite BioPharma Ltd

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Hanmi Pharmaceuticals Co Ltd

Humanetics Corp

IntelGenx Corp

Ion Channel Innovations LLC

iX Biopharma Ltd

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Monosol Rx LLC

NAL Pharmaceuticals Ltd

Palatin Technologies Inc

Pharmicell Co Ltd

Suda Ltd

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Erectile Dysfunction - Overview

Erectile Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Erectile Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Erectile Dysfunction - Companies Involved in Therapeutics Development

Apricus Biosciences Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Biopharm GmbH

Can-Fite BioPharma Ltd

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Hanmi Pharmaceuticals Co Ltd

Humanetics Corp

IntelGenx Corp

Ion Channel Innovations LLC

iX Biopharma Ltd

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Monosol Rx LLC

NAL Pharmaceuticals Ltd

Palatin Technologies Inc

Pharmicell Co Ltd

Suda Ltd

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Erectile Dysfunction - Drug Profiles

(tadalafil + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-ED - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKK-01PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCP-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPED-2015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-6932 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-0092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPN-729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLFIA-330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YBH-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Erectile Dysfunction - Dormant Projects

Erectile Dysfunction - Discontinued Products

Erectile Dysfunction - Product Development Milestones

Featured News & Press Releases

Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm

Jan 24, 2017: Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil

Nov 28, 2016: MonoSol Rx Submits New Drug Application for Tadalafil PharmFilm

Nov 09, 2016: Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug

Sep 13, 2016: iX Biopharma Announces Positive Results from Pivotal Study of Erectile Dysfunction Drug

Jul 27, 2016: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents

May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting

Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose

Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil

Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix

Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

Jan 27, 2015: Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies

Dec 09, 2014: Can-Fite to Initiate the Development Program of its Next Generation Drug CF602

Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Erectile Dysfunction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Erectile Dysfunction – Pipeline by Apricus Biosciences Inc, H1 2017

Erectile Dysfunction – Pipeline by Astellas Pharma Inc, H1 2017

Erectile Dysfunction – Pipeline by Biolab Farmaceutica Ltda, H1 2017

Erectile Dysfunction – Pipeline by Biopharm GmbH, H1 2017

Erectile Dysfunction – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Erectile Dysfunction – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017

Erectile Dysfunction – Pipeline by Futura Medical Plc, H1 2017

Erectile Dysfunction – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Erectile Dysfunction – Pipeline by Humanetics Corp, H1 2017

Erectile Dysfunction – Pipeline by IntelGenx Corp, H1 2017

Erectile Dysfunction – Pipeline by Ion Channel Innovations LLC, H1 2017

Erectile Dysfunction – Pipeline by iX Biopharma Ltd, H1 2017

Erectile Dysfunction – Pipeline by Mezzion Pharma Co Ltd, H1 2017

Erectile Dysfunction – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Erectile Dysfunction – Pipeline by Monosol Rx LLC, H1 2017

Erectile Dysfunction – Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Erectile Dysfunction – Pipeline by Palatin Technologies Inc, H1 2017

Erectile Dysfunction – Pipeline by Pharmicell Co Ltd, H1 2017

Erectile Dysfunction – Pipeline by Suda Ltd, H1 2017

Erectile Dysfunction – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Erectile Dysfunction – Pipeline by Yungjin Pharm Co Ltd, H1 2017

Erectile Dysfunction – Dormant Projects, H1 2017

Erectile Dysfunction – Dormant Projects, H1 2017 (Contd..1), H1 2017

Erectile Dysfunction – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Erectile Dysfunction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports